Cover Image
市場調查報告書

促血紅細胞生長素的日本市場:2015年∼2019年

Erythropoietin Market in Japan 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 239356
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
促血紅細胞生長素的日本市場:2015年∼2019年 Erythropoietin Market in Japan 2015-2019
出版日期: 2015年09月09日 內容資訊: 英文 65 Pages
簡介

促血紅細胞生長素 (EPO) ,也稱為紅細胞產生素或造血素,擔任血液中的紅血球生產的糖蛋白質。在嬰兒的階段,這個蛋白質由肝臟生產,不過,成人是由腎臟生產。貧血症患病的期間,人體過度生產促血紅細胞生長素,試圖保持血液中的紅血球濃度正常。體內的促血紅細胞生長素生產由於疾病和治療受妨礙時,透過注入造血劑 (ESA),努力維持紅血球水準。這種藥物,類似天然的促血紅細胞生長素與結構、功能。那些以基因改造型DNA技術生產,用於腎臟疾病、癌症、HIV、創傷、神經疾病伴隨的貧血症治療。日本的促血紅細胞生長素市場,2014∼2019年預計以1.16%的年複合成長率(CAGR) 成長。

本報告提供日本國內的智慧電網、管理服務市場相關分析、藥物、相關疾病概要和市場基本結構、市場規模趨勢 (今後5年的預測值)、各用途、各產品、各終端用戶詳細趨勢、推動、阻礙市場要素與其影響力、主要企業簡介、今後的市場機會等調查評估。

第1章 摘要整理

  • 分析結果的概要

第2章 分析範圍

  • 分析概要
  • 大供應商的主要產品

第3章 市場分析技術

  • 分析方法
  • 經濟指標

第4章 簡介

  • 市場趨勢的概要

第5章 生技仿製藥與生物製品產業

  • 概要
  • 生技仿製藥的新作用
  • 生技仿製藥、生技藥品對產業的影響要素
  • 生技仿製藥:商務、價格策略
  • 生技仿製藥產業:醫療機關、醫療費付款者、買主、規定當局的觀點

第6章 日本:該國概況

  • 日本的製藥產業
  • 日本的生技仿製藥、生技藥品產業
  • 法規環境
  • 醫療改革
  • 促血紅細胞生長素:日本的潛在市場 (潛在的市場規模)

第7章 全球促血紅細胞生長素藥市場

第8章 市場環境

  • 市場概要
  • 市場規模與其預測
  • 波特的五力分析

第9章 各用途的市場區隔

  • 末期腎臟疾病
  • 癌症
  • HIV
  • 創傷、神經疾病

第10章 各產品的市場區隔

  • 第1代促血紅細胞生長素劑型
  • 第2代的促血紅細胞生長素劑型
  • 生技仿製藥

第11章 各終端用戶的市場區隔

  • 醫院
  • 藥局

第12章 推動市場要素

  • 貧血症的發病數量的增加
  • 對促血紅細胞生長素調整劑的醫療費償付
  • 良好的成長機會

第13章 推動因素的影響力

第14章 市場課題

  • 複雜的製造工程
  • 繁雜的管理體制
  • 醫生對生技仿製藥處方的抵抗感

第15章 推動因素、課題的影響力

第16章 市場趨勢

  • 策略性聯盟
  • 創新的分子藥物的研究開發 (R&D) 的增加
  • 生技仿製藥的關注

第17章 供應商環境

  • 競爭方案
  • 市場佔有率分析

第18章 主要供應商分析

  • 中外製藥
  • JCR製藥
  • Kissei藥品工業
  • Kyowa Hakko Kirin

第19章 附錄

  • 簡稱集

第20章 關於Technavio

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR7268

About erythropoietin

Erythropoietin (EPO), also referred to as hematopoietin or hemopoietin, is a glycoprotein that is responsible for the production of erythrocytes in the body. In the fetal stage, this protein is produced in the liver. However, in adulthood it is produced in the kidneys. During anemic conditions, the body produces an excess of erythropoietin to maintain a normal level of red blood cells. When the endogenous production of erythropoietin is disrupted because of illness or medications, normal red blood cell levels are maintained by an injecting erythropoiesis-stimulating agents (ESAs). These agents are similar to natural erythropoietin in structure and function. They can be produced by recombinant DNA technology and are used in the treatment of anemia resulting from renal disease, cancer, HIV, injuries, or neurological conditions.

Technavio's analysts forecast the erythropoietin market in Japan to decline at a CAGR of (1.16) % over the period 2014-2019.

Covered in this report

In this report, Technavio covers the present scenario and growth prospects of the erythropoietin market in Japan for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of erythropoietin drugs and biosimilars used in the treatment of anemia due to renal disease, chemotherapy, antiretroviral therapy, wounds, or neurological conditions.

Technavio's report, Erythropoietin Market in Japan 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the erythropoietin market in Japan and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market.

Key vendors

  • Chugai Pharmaceutical
  • JCR Pharmaceuticals
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin

Other Prominent Vendors

  • Eisai
  • Otsuka
  • Taiho Pharmaceutical
  • Takeda

Market driver

  • Increased incidence of anemia due to illness
  • For a full, detailed list, view our report

Market challenge

  • High cost of therapy
  • For a full, detailed list, view our report

Market trend

  • Strategic alliances
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Biosimilars and biologics industry

  • Overview
  • Emerging role of biosimilars
  • Factors influencing biosimilars and biologics industry
  • Biosimilars: Business and pricing strategy
  • Biosimilars industry: Viewpoints of providers, payers, buyers, vendors, and regulatory bodies

PART 06: Japan: Country snapshot

  • Pharmaceutical industry in Japan
  • Biosimilars and biologics industry in Japan
  • Regulatory landscape
  • Healthcare reforms
  • Erythropoietin: Addressable market in Japan

PART 07: Global erythropoietin drugs market

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by application

  • End-stage renal disease
  • Cancer
  • HIV
  • Wounds and neural disease

PART 10: Market segmentation by product

  • First-generation erythropoietin formulation
  • Second-generation erythropoietin formulation
  • Biosimilars

PART 11: Market segmentation by end-user

  • Hospitals
  • Pharmacies

PART 12: Market drivers

  • Increased incidence of anemia
  • Reimbursement for erythropoietin preparations
  • Favorable growth opportunities

PART 13: Impact of drivers

PART 14: Market challenges

  • Complex manufacturing process
  • Complicated regulatory framework
  • Physician's reluctance to prescribe biosimilars

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Strategic alliances
  • Increased R&D of innovative molecule drugs
  • Focus on biosimilars

PART 17: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014

PART 18: Key vendor analysis

  • Chugai Pharmaceutical
  • JCR Pharmaceuticals
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Definition of biosimilars by organizations
  • Exhibit 03: Factors influencing biosimilars and biologics industry
  • Exhibit 04: Patent expiries of branded biologics
  • Exhibit 05: Impact of biosimilar cost savings on various sectors
  • Exhibit 06: Factors affecting success of biosimilars
  • Exhibit 07: Biosimilars industry: Point-of-view
  • Exhibit 08: Revenue of pharmaceuticals in Japan 2013 and 2020 ($ billions)
  • Exhibit 09: Pharmaceutical R&D expenditure in Japan 2000-2012 ($ millions)
  • Exhibit 10: Japan's percentage share in world imports of pharmaceuticals 2013
  • Exhibit 11: Japan's percentage share in world exports of pharmaceutical 2013
  • Exhibit 12: Biosimilars approved by PMDA in Japan
  • Exhibit 13: Review process of biosimilars in Japan
  • Exhibit 14: Number of people with cancer in Japan 2010-2013
  • Exhibit 15: Incidence of cancers in Japan 2011
  • Exhibit 16: Approved erythropoietin biosimilars
  • Exhibit 17: Erythropoietin drugs market in Japan 2014-2019 ($ millions)
  • Exhibit 18: Five forces analysis
  • Exhibit 19: Erythropoietin drugs market in Japan by end-user 2014
  • Exhibit 20: Erythropoietin drugs market in Japan by product in hospitals 2014
  • Exhibit 21: Erythropoietin drugs market segmentation in Japan by product in retail pharmacies 2014
  • Exhibit 22: Number of people receiving dialysis in Japan 2008-2012
  • Exhibit 23: Impact of drivers
  • Exhibit 24: Impact of drivers and challenges
  • Exhibit 25: Kyowa Hakko Kirin: YoY growth and revenue of NESP 2010-2014 ($ millions)
  • Exhibit 26: Kyowa Hakko Kirin: YoY growth and revenue of ESPO/NESP 2010-2012 ($ millions)
  • Exhibit 27: Chugai Pharmaceutical: YoY growth and revenue of Epogin 2010-2014 ($ millions)
  • Exhibit 28: Chugai Pharmaceutical: YoY growth and revenue of Mircera 2011-2014 ($ millions)
  • Exhibit 29: JCR Pharmaceuticals: YoY growth and revenue of Epoietin alfa BS injection JCR 2011-2014 ($ millions)
  • Exhibit 30: Kissei Pharmaceuticals: YoY growth and revenue of Epoietin alfa BS injection (JCR) 2011-2014 ($ millions)
  • Exhibit 31: Chugai Pharmaceuticals: Business segmentation by revenue 2014 (therapeutics)
  • Exhibit 32: Chugai Pharmaceuticals: Geographical segmentation by revenue 2014
  • Exhibit 33: Kissei Pharmaceutical: Business segmentation by revenue 2015
  • Exhibit 34: Kissei Pharmaceutical: Business segmentation by revenue 2014 and 2015 ($ millions)
  • Exhibit 35: Kissei Pharmaceutical: Geographical segmentation by revenue 2015
  • Exhibit 36: Kyowa Hakko Kirin: Business segmentation by revenue 2014
  • Exhibit 37: Kyowa Hakko Kirin: Business segmentation by revenue 2013 and 2014
  • Exhibit 38: Kyowa Hakko Kirin: Geographical segmentation by revenue 2014
Back to Top